OBSV - ObsEva's nolasiban shows potential to increase pregnancy rates following IVF

ObsEva SA (NASDAQ:OBSV) announces the publication of two peer-reviewed papers on nolasiban, an oxytocin receptor antagonist in development for improving live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF). The first paper, published in the Journal of Human Reproduction reports the results from a meta-analysis of three trials showing that nolasiban increased the likelihood of live birth following IVF. Key outcomes of the study were as follows: A single 900 mg dose of nolasiban administered before fresh single embryo transfer increased live birth rates compared to placebo. A patient-level combined analysis of the three studies showed a 5% absolute increase (15% relative increase) in ongoing pregnancy rate, with an odds ratio for nolasiban vs. placebo of 1.25 that was statistically significant (p=0.029). The analyses also showed that the effect size for nolasiban was similar for ongoing pregnancy rate and live birth rate. Nolasiban was well tolerated and there

For further details see:

ObsEva's nolasiban shows potential to increase pregnancy rates following IVF